Jennifer Thorne, MD, PhD

Professional Titles

• Chief, Division of Ocular Immunology

Primary Academic Title

Professor of Ophthalmology

Background

Centers and Institutes

Wilmer Eye Institute Research

CV

https://www.hopkinsmedicine.org/-/media/wilmer/documents/cvs/Thorne_CV.pdf

Clinical Trials Summary

7/15/88-7/31/15 Coordinating Center, Studies of Ocular Complications of AIDS. PI: Curtis L. Meinart' Role:  Deputy Director, Medical Ophthalmologist, Epidemiologist; Major Goal: To evaluate vision outcomes among patients with AIDS and with ocular opportunistic infections secondary to AIDS, most commonly cytomegalovirus retinitis.   

7/1/03-12/31/17 Coordinating Center, Multicenter Uveitis Steroid Treatment (MUST) Trial. PI: Janet T. Holbrook. Role:  Medical Officer; Chair, Medical Therapy Quality Assurance Committee; Major Goal:  Compare the fluocinolone acetonide implant to “standard therapy” for the treatment of patients with severe, vision-threatening intermediate, posterior, or panuveitis.  

10/1/10-8/31/15 Systemic Immunosuppressive Therapy for Eye Disease (SITE) 2 Cohort Study. PI: John H. Kempen. Role:  Principal Investigator at the Johns Hopkins Site, Major Goal: Evaluate the long-term risk of cancer diagnosis and cancer-related morbidity in patients receiving immunosuppressive therapy for non-infectious inflammatory eye diseases.  

7/1/11-6/30/16 North American AIDS Cohorts Collaboration on Research and Design. PI: Richard D. Moore. Consortium HIV/AIDS databases from academic medical centers and community based facilities that deliver HIV care in the U.S. and Canada to identify questions of intraregional and interregional importance that are critical to the contemporary treatment of HIV infection in North America, and design and implement the analyses necessary to answer these questions.

10/1/12-9/30/16 A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab as Maintenance Therapy in Subjects Requiring High Doses of Corticosteroids for Active Non-Infectious Intermediate, Posterior, and Pan-Uveitis. PI: Jennifer E. Thorne

10/1/12-9/30/16 A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Non-Infectious Intermediate, Posterior, and Pan-Uveitis. PI: Jennifer E. Thorne

10/1/12-9/30/16 A Multicenter Open-Label Study of the Long-Term Safety and Efficacy of the Human Anti-TNF Monocloncal Antibody in Subjects with Non-Infectious, Intermediate, Posterior, and Pan-Uveitis. PI: Jennifer E. Thorne

12/1/12-11/30/16 A Randomized, Double masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-Infectious Intermediate, Posterior, or Pan Uveitis. PI: Jennifer E. Thorne

12/1/12-11/30/16 A Randomized, Double masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Subjects with Non-Infectious Intermediate, Posterior, or Pan-Uveitis currently Inactive. PI: Jennifer E. Thorne

10/1/13-9/30/17 Proof of Concept Study of the Effectiveness of Ozurdex in lieu of Oral Corticosteroids for the Control of Active Intermediate, Posterior and Panuveitis Requiring Immunosuppressive Drug Therapy. PI: Jennifer E. Thorne.

Videos

• Meet Dr. Thorne

Recent News Articles and Media Coverage

• Collaboration That Changes Lives: Antoinette’s Story, Johns Hopkins Medicine (Aug. 2021)

  Why uveitis is a leading and underestimated cause of visual morbidity in patients, Modern Retina (Mar. 2021) 

  Ankylosing spondylitis & uveitis: An ophthalmologist’s perspective, The Rheumatologist (September 2019) 

  Not Your Ordinary Patient, Wilmer Magazine (Jul. 2019)

  HIV and the eye: lessons learned, challenges remain, EyeNet Magazine (Jan. 2014) 

  Rare disorder nearly takes Baltimore woman’s sight, Baltimore Sun (May 2012) 

   

Research Interests

birdshot chorioretinitis, JIA uveitis, ocular inflammatory disease, pediatric uveitis, uveitic macular edema

PubMed

http://www.ncbi.nlm.nih.gov/pubmed/?term=jennifer+e+thorne

Selected Publications

• Autoimmune bullous diseases with skin and eye involvement: Cicatricial pemphigoid, pemphigus vulgaris, and pemphigus paraneoplastica. Broussard KC, Leung TG, Moradi A, Thorne JE, Fine JD. Clin Dermatol. 2016 Mar-Apr;34(2):205-13. doi: 10.1016/j.clindermatol.2015.11.006. Epub 2015 Dec 19.

• Direct and indirect resource use, healthcare costs and work force absence in patients with non-infectious intermediate, posterior or panuveitis. Thorne JE, Skup M, Tundia N, Macaulay D, Revol C, Chao J, Joshi A, Dick AD. Acta Ophthalmol. 2016 Mar 2. doi: 10.1111/aos.12987. [Epub ahead of print]

• Dissociations of the Fluocinolone Acetonide Implant: The Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study. Holbrook JT, Sugar EA, Burke AE, Vitale AT, Thorne JE, Davis J, Jabs DA; Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group. Am J Ophthalmol. 2015 Dec 31. pii: S0002-9394(15)30049-0. doi: 10.1016/j.ajo.2015.12.028. [Epub ahead of print]

• Remission of Intermediate Uveitis: Incidence and Predictive Factors. Kempen JH, Gewaily DY, Newcomb CW, Liesegang TL, Kaçmaz RO, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Sen HN, Suhler EB, Thorne JE, Foster CS, Jabs DA, Payal A, Fitzgerald TD; Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Research Group. Am J Ophthalmol. 2016 Jan 6. pii: S0002-9394(16)30002-2. doi: 10.1016/j.ajo.2015.12.034. [Epub ahead of print]

• Using a patient-centered approach to benefit-harm assessment in treatment decision-making: a case study in uveitis. Yu T, Holbrook JT, Thorne JE, Puhan MA. Pharmacoepidemiol Drug Saf. 2016 Jan 22. doi: 10.1002/pds.3959. [Epub ahead of print]

Honors

• Vitals Patients' Choice Award, 1/18/14
• Global Who's Who, 1/17/13
• America's Top Ophthalmologists, 1/18/11
• American Academy of Ophthalmology Best Paper Award, 1/18/10
• Top Doctors in Ophthalmology, 1/15/10
• American Academy of Ophthalmology Achievement Award, 1/18/09
• Best Doctors in Baltimore, 1/4/07
• Best Doctors in America, 1/1/07
• Delta Omega Honorary Society in Public Health, 1/1/05
• AIDS Training Award, 1/1/01
• Maumenee Clinician Award, 1/1/01
• Heed Ophthalmic Foundation Fellowship, 1/1/01

Lectures & Presentations

• NULL, Invited Speaker, Uveitis Forum sponsored by the Ophthalmological Society of Taiwan, Taipei, Taiwan, 12/2/14
• NULL, Invited Speaker, World Ophthalmology Congress, Tokyo, Japan, 4/1/14
• NULL, Invited Speaker, Uveitis Forum, International Ocular Inflammation Society, Ho Chi Minh City, Viet Nam, 10/1/13
• NULL, Invited Speaker, Uveitis Subspecialty Day, American Academy of Ophthalmology Meeting, Chicago, Illinois, 10/1/14
• NULL, Visiting Professor, Hadassah Medical Center, Jerusalem, Israel, 6/1/14
• NULL, Visiting Professor, SUNY Downstate, Brooklyn, New York, 1/1/15
• NULL, Visiting Professor, University of Paris, Paris, France, 1/1/12

Memberships

• Pan-American Association of Ophthalmology
• International Ocular Inflammation Society (IOIS)
• American Uveitis Society (AUS)
• Society for Heed Fellows
• American Academy of Ophthalmology
• Association for Research in Vision and Ophthalmology
• American Society of Cataract and Refractive Surgery
• American Medical Association

Professional Activities

• AbbVie, Advisory Board, 1/1/13 - 12/31/13
• Allergan, Advisory Board, 1/1/09 - 12/31/09
• American Academy of Ophthalmology, Ophthalmic Technology Assessment Committee, 1/1/10 - 1/31/13
• American Academy of Ophthalmology, Reviewer for Uveitis Subspecialty, Ophthalmic News and Education (O.N.E.) Network, 1/1/07 - 12/31/07
• American Board of Ophthalmology, Examiner, 1/1/07
• American Uveitis Society, Executive Board, 1/1/07
• Association of University Professors in Ophthalmology (AUPO), Board of Managers, 1/1/07 - 12/31/07
• Association of University Professors of Ophthalmology, Member, Board of Managers, Fellowship Certification Committee, 1/1/07
• Gilead, Consulant, 1/1/13 - 12/31/13
• Mallinckrodt Pharmaceuticals, Advisory Board, 1/1/15
• Practicing Ophthalmologists Curriculum (POC) for the American Academy of Ophthalmology, Member in the Uveitis Subspecialty, 1/1/09 - 12/31/09
• XOMA, Advisory Board/Consultant, 1/1/11 - 12/31/11